NS5B Polymerase Inhibitors to Begin Hep C Trials
December 15, 2011
Vertex, Alios BioPharma commence studies for Hepatitis C treatment
PBR Staff Writer
Published 12 December 2011
Vertex Pharmaceuticals and Alios BioPharma, together have initiated two clinical studies for the nucleotide analogues ALS-2200 and ALS-2158, inhibitors of the hepatitis C NS5B polymerase.
ALS-2200 and ALS-2158 are pan-genotypic nucleotide analogues, designed to inhibit the replication of the hepatitis C virus by acting on the NS5B polymerase.
The two Phase 1 studies will be randomized, double-blind, placebo-controlled studies, with the primary goals of evaluating the safety and tolerability of single ascending doses of ALS-2200 and ALS-2158 in healthy volunteers and of multiple ascending doses in people with chronic genotype-1 hepatitis C.
Continue reading this entire article:
Hepatitis C and Coronary Artery Disease Linked
HCV Management Pearl: Teeth Grinding and Its Aggravator